MADRIGAL PHARMACEUTICALS, INC. (MDGL) Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Madrigal Pharmaceuticals, Inc. NASDAQ:MDGL Healthcare · Biotechnology
Mkt Cap $9.94B
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release ⚠ 1
Madrigal to Present Multiple Abstracts at AASLD's The Liver Meeting 2026, Including New Real-World Evidence Reinforcing Rezdiffra as a Foundational Therapy for MASH
Madrigal Pharmaceuticals will present thirteen abstracts on Rezdiffra (resmetirom) at AASLD's The Liver Meeting 2026, held Nov. 5-9 in Denver.
The data span its RESONANCE real-world evidence program, with the largest dataset covering more than 12,000 patients and examining effectiveness, tolerability, adherence and persistence in routine clinical practice.
Clinical abstracts also show improvements in noninvasive liver-health measures, cardiovascular risk markers and patient-reported outcomes, reinforcing Rezdiffra's positioning as a foundational MASH therapy.
• 5d ago AI analysis › Press Release
Madrigal Pharmaceuticals to Release Third-Quarter 2026 Financial Results and Host Webcast on November 3, 2026
Madrigal Pharmaceuticals will release third-quarter 2026 financial results on Tuesday, November 3, 2026, before the U.S. market open.
Management will host a live webcast at 8 a.m. ET the same day, with a replay available roughly two hours afterward.
The release contains no financial results; it is a scheduling notice only.
• 12d ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted inducement equity awards to 26 new non-executive employees under its 2025 Inducement Plan, approved by the independent Compensation Committee per Nasdaq Listing Rule 5635(c)(4).
The aggregate grant was 9,642 time-based restricted stock units vesting in four equal annual installments, contingent on continued employment.
This is a routine hiring-related disclosure with no bearing on Madrigal's MASH franchise, including Rezdiffra's ongoing Phase 3 F4c outcomes trial.
• 17d ago AI analysis › Press Release ⚠ 1
Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants
Madrigal announced publication of a pre-specified secondary analysis of the Phase 3 MAESTRO-NASH trial (738 patients) in the Journal of Hepatology showing Rezdiffra efficacy is consistent across common MASH genetic risk variants including PNPLA3, HSD17B13, TM6SF2, MTARC1 and MBOAT7.
In the PNPLA3 subgroup, MASH resolution rates were 38.4%, 30.8% and 30.5% for Rezdiffra versus 12.9%, 5.1% and 11.7% for placebo across low, intermediate and high-risk genotypes, with similar fibrosis-improvement results.
The findings support broad applicability of Rezdiffra as a foundation of MASH treatment, and the company plans an FDA consultation on a Phase 2 combination trial with its precision-medicine pipeline asset MGL-0795.
• 26d ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted inducement equity awards to 27 new non-executive employees on September 1 and September 14, 2026, under its 2025 Inducement Plan as approved by the independent Compensation Committee per Nasdaq Listing Rule 5635(c)(4).
The aggregate grants comprise options to purchase 2,754 shares at a $538.71 exercise price -- equal to the closing price on the grant date -- plus 16,149 time-based restricted stock units vesting in four equal annual installments.
This is a routine hiring-related equity disclosure with no new clinical, financial, or commercial information on Rezdiffra or the MASH franchise.
• 1mo ago AI analysis › Press Release
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference
Madrigal Pharmaceuticals (Nasdaq: MDGL) will participate in the 2026 Cantor Global Healthcare Conference on Thursday, Sept. 10, 2026 at 1:00 P.M. EDT.
The presentation will be webcast live and a replay will be available afterward via the company's investor relations events page.
No new clinical, regulatory, or financial data accompanied the announcement; it is a routine scheduling notice for the maker of Rezdiffra, the first FDA- and European Commission-approved treatment for MASH with moderate to advanced fibrosis.
• 1mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal granted 4,676 time-based restricted stock units to 13 new non-executive employees as employment inducements under Nasdaq Rule 5635(c)(4).
The awards, approved by the compensation committee on August 15, vest in four equal annual installments subject to continued employment.
This filing is a routine administrative disclosure related to onboarding new talent rather than a strategic material event.
• 2mo ago AI analysis › Press Release
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors
Madrigal Pharmaceuticals appointed Dr. John C. Reed, M.D., Ph.D., to its Board of Directors, bringing on a top executive from Johnson & Johnson.
Dr. Reed currently serves as Executive Vice President of Innovative Medicine R&D at J&J and previously held leadership roles at Sanofi and Roche, bringing decades of global drug development experience.
The company expects his deep scientific expertise to bolster its strategic direction as it continues the commercial launch of Rezdiffra and advances its MASH pipeline.
• 2mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted 4,263 restricted stock units to ten new non-executive employees as inducement awards under Nasdaq Rule 5635(c)(4).
The awards were approved by the independent Compensation Committee and vest in four equal installments on the first through fourth anniversaries of the grant date.
This is a routine compensation disclosure for new hires and does not reflect a change in business operations.
• 2mo ago AI analysis › Press Release
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference
Madrigal Pharmaceuticals announced it will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026.
The presentation is scheduled to begin at 12:00 P.M. EDT and will be webcast live through the company’s investor relations website.
A replay of the webcast will be made available following the conclusion of the event.
• 2mo ago AI analysis › Press Release ● Major ⚠ 2
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal reported Q2 2026 revenue of $364.3 million, up 71% year-over-year, driven by strong demand for Rezdiffra which now has over 49,000 patients on therapy, more than doubling from the prior year.
The company advanced its pipeline by initiating Phase 1 dosing for MGL-2086, an oral GLP-1 intended for combination therapy, and secured new patents extending resmetirom protection into the 2040s.
Operating expenses increased to $420.6 million to support commercialization efforts, resulting in a net loss of $57.9 million, though the company maintains a strong cash position of $838.9 million.
• 3mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted inducement equity awards to ten new non-executive employees on July 15, 2026, as approved by its independent Compensation Committee.
The awards consist of options to purchase 4,770 shares of common stock at $550.25 per share, along with 7,433 time-based RSUs and 1,908 performance-based RSUs.
Vesting schedules include quarterly vesting for options after the first anniversary and annual installments for time-based RSUs, while performance-based units depend on total shareholder return relative to a peer group.
• 3mo ago AI analysis › Press Release
Madrigal Pharmaceuticals to Release Second-Quarter 2026 Financial Results and Host Webcast on July 30, 2026
Madrigal Pharmaceuticals announced that it will release its second-quarter 2026 financial results on Thursday, July 30, 2026, prior to the market open.
Management will host a live webcast at 8 a.m. Eastern Time to discuss the company’s financial and operating results, accessible through the Investor Relations section of its website.
• 3mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio
Madrigal Pharmaceuticals announced the issuance of three new U.S. patents for Rezdiffra (resmetirom), covering dosing methods for F2/F3 MASH and a new indication for well-compensated cirrhosis.
The patents extend intellectual property protection to 2045 for F2/F3 dosing with CYP2C8 inhibitors and to 2042 for the F4c indication and co-administration with rosuvastatin.
CEO Bill Sibold stated that expanding the patent estate is a core pillar of the company's strategy, providing a runway for innovation and securing long-term value.
• 3mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted inducement equity awards to seven new non-executive employees on July 1, 2026, approved by its independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
The awards consist of options to purchase 604 shares of common stock and 2,952 time-based restricted stock units, with an exercise price equal to the closing price of $514.39 per share on the grant date.
Vesting schedules are standard, with options vesting 25% on the first anniversary and 6.25% quarterly thereafter, while restricted stock units vest in four equal annual installments.
• 3mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted inducement equity awards to five new non-executive employees on June 15, 2026, under its 2025 Inducement Plan.
The awards aggregate 1,397 time-based restricted stock units and were approved by the independent Compensation Committee pursuant to Nasdaq Listing Rule 5635(c)(4).
All restricted stock units vest in four equal installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.
• 4mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted 6,881 time-based restricted stock units to 20 new non-executive employees.
The awards were issued as inducements under Nasdaq Listing Rule 5635(c)(4) and approved by the independent Compensation Committee.
The RSUs vest in four equal annual installments over four years, contingent on continued employment.
• 4mo ago AI analysis › Press Release
Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026
Madrigal Pharmaceuticals will present at the 47th Annual Global Goldman Sachs Health Care Conference on June 10, 2026, at 11:20 A.M. EDT.
The presentation will be webcast live and a replay will be available afterward.
No new clinical data, regulatory milestones, or financial guidance were disclosed in this announcement.
• 4mo ago AI analysis › Press Release
Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH
Madrigal presented new data at the EASL Congress 2026 showing Rezdiffra reduces cardiovascular risk markers, including LDL-C and Lp(a), in MASH patients regardless of statin use.
Secondary analysis of the Phase 3 MAESTRO program showed that among statin-treated patients, 44.4% with baseline LDL-C ≥70mg/dL shifted to <70mg/dL at week 52, while 50.0% of those with baseline LDL-C ≥100mg/dL shifted below that threshold.
In patients with compensated MASH cirrhosis, Rezdiffra improved the ANTICIPATE-NASH risk score by up to 37.6% over two years, reducing the proportion of high-risk patients from 75% at baseline to 54.5% at Year 2.
Real-world evidence from multiple studies demonstrated sustained improvements in liver stiffness and biomarkers, with 49% of patients achieving ≥25% reduction in liver stiffness over nine months.
• 5mo ago AI analysis › Press Release
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals granted 5,308 time-based restricted stock units to 15 new non-executive employees.
The awards were issued as inducements under the company’s 2025 Inducement Plan and approved by the Compensation Committee.
All RSUs vest in four equal annual installments over four years, contingent on continued employment.
• 5mo ago AI analysis › Press Release
Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk
Madrigal Pharmaceuticals will present multiple abstracts at the EASL Congress 2026, highlighting secondary analyses from its pivotal Phase 3 MAESTRO-NASH and MAESTRO-NAFLD-1 trials.
The data demonstrates improvements in cardiovascular risk markers, including Lp(a), LDL-C, and ApoB, as well as improvements in ANTICIPATE-NASH risk scores for patients with compensated MASH cirrhosis.
Additional presentations cover early real-world evidence and the utility of non-invasive biomarkers in predicting fibrosis improvement, reinforcing Rezdiffra’s position as a foundational therapy for MASH.
• 5mo ago AI analysis › Press Release ● Critical
Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Madrigal reported first-quarter 2026 revenue of $311.3 million, up 127% year-over-year, driven by Rezdiffra which now has over 42,000 patients on therapy.
The company expanded its pipeline via a licensing agreement with Arrowhead Pharmaceuticals for ARO-PNPLA3, a clinical-stage siRNA asset targeting the PNPLA3 mutation.
Operating expenses increased to $404.1 million, including $54.3 million in upfront business development costs, resulting in a net loss of $94.4 million.
• 5mo ago AI analysis › Press Release ● Major
Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline
Madrigal Pharmaceuticals licensed Arrowhead’s clinical-stage siRNA asset ARO-PNPLA3, targeting the PNPLA3 genetic driver of MASH, via an exclusive global agreement.
Phase 1 data showed a 46% reduction in liver fat in homozygous patients, with Madrigal planning combination studies with its flagship drug Rezdiffra.
Deal terms include a $25 million upfront payment, up to $975 million in potential milestones, and royalties on future sales.
• 5mo ago AI analysis › Press Release
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
globenewswire.com • 6mo ago 
